Vasa’s VS-041 shows positive Phase Ic results in HFpEF trial

​

Vasa Therapeutics has reported positive topline findings demonstrating clinical proof of concept for its lead therapy, VS-041, in a Phase Ic study in patients with HFpEF.

The post Vasa’s VS-041 shows positive Phase Ic results in HFpEF trial appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.